{"id":631,"date":"2015-07-23T18:47:19","date_gmt":"2015-07-23T13:17:19","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=631"},"modified":"2024-09-18T13:23:36","modified_gmt":"2024-09-18T07:53:36","slug":"cytotoxic-t-lymphocyte-associated-antigen-4-ctla-4-competitive-landscape-pipeline-and-market-analysis-2015","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/cytotoxic-t-lymphocyte-associated-antigen-4-ctla-4-competitive-landscape-pipeline-and-market-analysis-2015","title":{"rendered":"Cytotoxic T lymphocyte-associated antigen-4 Market Forecast & Insights"},"content":{"rendered":"

Cancer is one of the pioneer causes of obliteration. Although a lot of therapies are being developed in this area but still there is a high unmet need. Currently companies are getting inclined towards Immunotherapies which are target specific (monoclonal and conjugated antibodies) and effective. One such therapy area is Cytotoxic T lymphocyte associated antigen-4 (<\/strong>CTLA-4). It is found on the surface of T \u2013cells and is continuously involved in the inhibitory T-cell responses.CTLA-4<\/strong>\u00a0 (Cytotoxic T-lymphocyte-associated protein 4<\/strong>), also known as\u00a0CD152<\/strong>\u00a0 is a protein receptor that down regulates the immune system by consistently affecting the T cell responses. It is generally encoded by CTLA-4 gene in humans.<\/p>\n

\"Untitled\"<\/p>\n

The current Oncology market is steered by Bristol Myers Squibb with Yervoy (monoclonal antibody) approved for melanoma. The annual sales for Yervoy have increased by 23% in US and 56% in Non-US cities in 2014 as compared to 2013.<\/h4>\n

<\/h4>\n

\"gfxhyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy\"<\/p>\n

Several other companies are actively working which includes Astrazeneca, Merck, Roche & Pfizer. There are several drugs under pipeline among which Tremelimumab <\/strong>had shown inordinate results in clinical studies for treating malignant mesothelioma.<\/p>\n

DelveInsight\u2019s, Cytotoxic T lymphocyte associated antigen-4 (CTLA-4)\u00a0<\/strong>– Competitive Landscape, Pipeline and Market Analysis, 2015 <\/strong>provides the in-depth analysis of the pipeline assets across Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) targets & inhibitors<\/strong>. The prime foucs of this report is to track competitor pipeline molecules, related research activities, t, collaborations, in-licensing and out-licensing deals. Cytotoxic T lymphocyte associated antigen-4 (CTLA-4)\u00a0<\/strong>– Competitive Landscape, Pipeline and Market Analysis, 2015 <\/strong>Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to optimize portfolios and to gain competitive advantage.<\/p>\n

DelveInsight is offering the Report at a price of USD 1450\u00a0as a single user license, USD 2900 as a site license and USD 4000 as a Global\/Enterprise License.<\/p>\n

For more information on our Oncology Reports email us at info@delveInsight.com<\/a><\/p>\n

About:<\/strong><\/p>\n

DelveInsight is a leading Business Consulting and Market Research Firm.\u00a0 We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this, DelveInsight also deals in providing custom research services in coherence with interest area of the clients.<\/p>\n","protected":false},"excerpt":{"rendered":"

Cancer is one of the pioneer causes of obliteration. Although a lot of therapies are being developed in this area but still there is a high unmet need. Currently companies are getting inclined towards Immunotherapies which are target specific (monoclonal and conjugated antibodies) and effective. One such therapy area is Cytotoxic T lymphocyte associated antigen-4 […]<\/p>\n","protected":false},"author":1,"featured_media":619,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[134,137,149,173,204,207,583,609],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-631","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-business-consultant","tag-cancer","tag-cd152","tag-collaborations","tag-delveinsight","tag-delveinsight-oncology-reports","tag-tremelimumab","tag-yervoy","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nCTLA-4 Market Trends and Forecast Insights<\/title>\n<meta name=\"description\" content=\"One such therapy area is Cytotoxic T lymphocyte associated antigen-4 (CTLA-4). It is found on the surface of T \u2013cells and is continuously involved...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/cytotoxic-t-lymphocyte-associated-antigen-4-ctla-4-competitive-landscape-pipeline-and-market-analysis-2015\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CTLA-4 Market Trends and Forecast Insights\" \/>\n<meta property=\"og:description\" content=\"One such therapy area is Cytotoxic T lymphocyte associated antigen-4 (CTLA-4). It is found on the surface of T \u2013cells and is continuously involved...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/cytotoxic-t-lymphocyte-associated-antigen-4-ctla-4-competitive-landscape-pipeline-and-market-analysis-2015\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-07-23T13:17:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T07:53:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/09022438\/delveinsight_logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"227\" \/>\n\t<meta property=\"og:image:height\" content=\"65\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CTLA-4 Market Trends and Forecast Insights","description":"One such therapy area is Cytotoxic T lymphocyte associated antigen-4 (CTLA-4). It is found on the surface of T \u2013cells and is continuously involved...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/cytotoxic-t-lymphocyte-associated-antigen-4-ctla-4-competitive-landscape-pipeline-and-market-analysis-2015","og_locale":"en_US","og_type":"article","og_title":"CTLA-4 Market Trends and Forecast Insights","og_description":"One such therapy area is Cytotoxic T lymphocyte associated antigen-4 (CTLA-4). It is found on the surface of T \u2013cells and is continuously involved...","og_url":"https:\/\/www.delveinsight.com\/blog\/cytotoxic-t-lymphocyte-associated-antigen-4-ctla-4-competitive-landscape-pipeline-and-market-analysis-2015","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-07-23T13:17:19+00:00","article_modified_time":"2024-09-18T07:53:36+00:00","og_image":[{"width":227,"height":65,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/09022438\/delveinsight_logo.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/cytotoxic-t-lymphocyte-associated-antigen-4-ctla-4-competitive-landscape-pipeline-and-market-analysis-2015","url":"https:\/\/www.delveinsight.com\/blog\/cytotoxic-t-lymphocyte-associated-antigen-4-ctla-4-competitive-landscape-pipeline-and-market-analysis-2015","name":"CTLA-4 Market Trends and Forecast Insights","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/cytotoxic-t-lymphocyte-associated-antigen-4-ctla-4-competitive-landscape-pipeline-and-market-analysis-2015#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/cytotoxic-t-lymphocyte-associated-antigen-4-ctla-4-competitive-landscape-pipeline-and-market-analysis-2015#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/09022438\/delveinsight_logo.jpg","datePublished":"2015-07-23T13:17:19+00:00","dateModified":"2024-09-18T07:53:36+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"One such therapy area is Cytotoxic T lymphocyte associated antigen-4 (CTLA-4). It is found on the surface of T \u2013cells and is continuously involved...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/cytotoxic-t-lymphocyte-associated-antigen-4-ctla-4-competitive-landscape-pipeline-and-market-analysis-2015"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/cytotoxic-t-lymphocyte-associated-antigen-4-ctla-4-competitive-landscape-pipeline-and-market-analysis-2015#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/09022438\/delveinsight_logo.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/09022438\/delveinsight_logo.jpg","width":227,"height":65},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/09022438\/delveinsight_logo.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CD152<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">collaborations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">delveinsight oncology reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Tremelimumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Yervoy<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">CD152<\/span>","<span class=\"advgb-post-tax-term\">collaborations<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">delveinsight oncology reports<\/span>","<span class=\"advgb-post-tax-term\">Tremelimumab<\/span>","<span class=\"advgb-post-tax-term\">Yervoy<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jul 23, 2015","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Jul 23, 2015 6:47 pm","modified":"Updated on Sep 18, 2024 1:23 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=631"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/631\/revisions"}],"predecessor-version":[{"id":28293,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/631\/revisions\/28293"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/619"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=631"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=631"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}